Various isolation strategies are used to prevent infections during bone marrow transplantation; data on their efficacy are lacking. We studied whether use of high efficiency particulate air filtration ( and increases survival after allogeneic bone marrow transplants for leukemia.
Bone marrow transplant recipients have a high risk of infections early after transplant. Data from the International Bone Marrow Transplant Registry (IBMTR) indicate that infections are the primary cause in about 15%, and a contributory cause in another 35%, of deaths occurring in the first post-transplant year.
Several strategies are used to prevent infections during transplants including physical barriers to infectious agents (protective isolation) and prophylactic antibiotics. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Approaches differ in costs and psychosocial effects on patients. 18, 19 There is controversy whether these strategies effectively decrease infections. This study focused on whether use of high efficiency particulate air filtration (HEPA) and/or laminar airflow (LAF) units rather than conventional isolation techniques influenced transplant outcome.
Patients and methods

Population
The study included 5065 patients receiving allogeneic bone marrow transplants between 1988 and 1992 and reported to the IBMTR with the following: (1) chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL); (2) graft-versus-host disease (GVHD) prophylaxis with cyclosporine with or without other drugs or T cell depletion. We excluded patients treated without protective isolation (n = 63) or with isolation strategies other than the categories described below (n = 193), those receiving other types of GVHD prophylaxis (n = 246), those with insufficient HLA data to determine donor-recipient histocompatibility (n = 153), and those without information on pretransplant disease state or age (n = 77). Patients were reported by 222 teams.
Isolation strategies
Two isolation strategies were studied: (1) conventional protective isolation using single rooms, and any combination of hand-washing, gloves, mask, and gown to prevent infection transmission (conventional isolation, n = 827); and (2) protective isolation in rooms designed to lower exposure to airborne infectious agents using HEPA filtration systems with or without LAF equipment (HEPA/LAF, n = 4238).
Outcomes
Transplant outcomes analyzed included acute and chronic GVHD, fungal pneumonia, 1-year transplant-related mortality (TRM), and 1-year survival. Acute GVHD was defined as moderate to severe (grade II-IV) disease using published criteria; 20 patients surviving у21 days with engraftment were considered at risk. Chronic GVHD was determined by clinical criteria in patients surviving у90 days with engraftment. 21 TRM was defined as death in patients without leukemia relapse, with censoring at time of relapse or last follow-up. 22 Follow-up to 100 days posttransplant was available for 100% of patients; follow-up to 1 year was available for 84%.
Statistical methods
Patient-, disease-and transplant-related variables of the two study groups were compared using the 2 statistic for categorical and the Mann-Whitney U test for continuous variables. Probabilities of transplant outcomes were calculated using the Kaplan-Meier estimator; the log-rank test was used for univariate comparisons. Associations of isolationtype with TRM and survival were evaluated using Cox proportional hazards regression. 23 Since recovery of immune function differs after HLA-identical sibling and alternative donor transplants, these cohorts were analyzed separately. Potential confounding variables considered in the analysis were: donor-recipient relationship and histocompatibility, recipient age, donor-recipient sex-match, donor and recipient cytomegalovirus (CMV) serology, pretransplant Karnofsky performance score, disease, remission state, white blood cell count (WBC) at diagnosis, conditioning regimen, GVHD prophylaxis, year of transplant and the prophylactic use of systemic antibiotics, oral nonabsorbable antibiotics, cotrimoxazole, acyclovir, intravenous immune globulins, hematopoietic growth factors including G-CSF and GM-CSF, transplant center size (number of transplants done annually) and transplant center site. Forward stepwise variable selection at a 0.05 significance level was used to identify covariates associated with outcome. In each step of the analysis, the covariate for isolation type was included in the model. For each model the assumption of proportional hazards was tested using a time-dependent covariate; this indicated a differential effect of isolation type in the early and late post-transplant period. Models were therefore constructed breaking the post-transplant course into two time periods using the maximized partial likelihood method to find the most appropriate breakpoint. First order interactions between type of isolation and all significant covariates were considered.
Results
Patient-, disease-and transplant-related variables are shown in Tables 1 and 2 . Among patients receiving HLA-identical sibling transplants, there were statistically significant differences between those treated in conventional vs HEPA/LAF isolation in patient age, pretransplant performance score, year of transplant, conditioning regimen, GVHD prophylaxis, use of systemic and oral nonabsorbable antibiotics, use of cotrimoxazole, hematopoietic growth factors and transplant center site (Table 1) . Among those receiving alternative donor transplants, the cohorts differed for disease, disease state, pretransplant performance score, CMV status, year of transplant, conditioning regimen, GVHD prophylaxis, use of cotrimoxazole, acyclovir, intravenous immune globulins and transplant center site ( Table 2) . Table 3 shows actuarial probabilities (± 95% confidence interval) of acute and chronic GVHD, fungal pneumonia, TRM and 1-year survival by donor type and isolation technique in univariate analysis. Rates of acute or chronic GVHD were similar in patients treated in conventional vs HEPA/LAF isolation. Among patients receiving alternative donor transplants, the probability of fungal pneumonia was lower in the HEPA/LAF cohort. TRM was lower and 1-year survival higher for patients treated with HEPA/LAF isolation, whether the transplant was from an HLA-identical sibling or alternative donor (Table 3, Figure 1 ). Table 4 shows the relative risk of TRM for patients treated in HEPA/LAF vs conventional isolation in multivariate analyses, adjusting for the effect of other significant variables. The relationship between isolation and TRM is time-dependent. Patients treated with HEPA/LAF had lower risks of TRM in the first 100 days post-transplant with no effect thereafter. Table 5 shows the relative risk of mortality in the first post-transplant year for patients treated in HEPA/LAF vs conventional isolation. Again, HEPA/LAF isolation decreased overall mortality in the first 100 days post-transplant. There were no interactions between the effect of isolation and prophylactic use of antibiotics, cotrimoxazole or immune globulins in either model. Transplant center site, categorized as high or low geographic latitude, but not transplant center size, was significantly associated with TRM and mortality in the first post-transplant year. HEPA/LAF decreased TRM and mortality regardless of transplant center site.
There were no significant differences in the primary causes of death, for patients dying within 1 year post-transplant, between patients treated in HEPA/LAF vs conventional isolation.
Discussion
Isolation techniques used for allogeneic bone marrow transplant recipients vary.
3,6,12,17 Several studies comparing a n eval refers to number of patients for whom data regarding the specified variable were available. b (Ͼ50 × 10 9 /l for acute leukemia; Ͼ100 × 10 9 /l for chronic leukemia). c Used prophylactically. d Excluding cotrimoxazole. e G-CSF or GM-CSF, starting within 1 week of transplant. f North or south of equator. CR = complete remission; WBC = white blood cell count; CMV = cytomegalovirus; Bu = busulfan; Cy = cyclophosphamide; TBI = total body irradiation; CsA = cyclosporin A; MTX = methotrexate; i.v. = intravenous. different techniques are reported with contradictory results. [24] [25] [26] [27] [28] [29] [30] [31] This study represents the largest group of patients analyzed for associations between isolation technique and outcome.
Our major finding is that survival is higher in patients treated in HEPA/LAF units than in those treated with conventional isolation. This benefit persists after adjusting for other differences in patient-, disease-and transplant-related variables. Higher survival results from less TRM in the first 100 days post-transplant. The effect is seen in both HLAidentical sibling and alternative donor transplants and appears to be stronger in the latter. This effect of isolation technique is independent of use of prophylactic antibiotics or immune globulins.
Previous studies of isolation techniques analyzed small and/or heterogenous patient groups, 24-26 but three prospec- (7) 33/883 (4) a n eval refers to number of patients for whom data regarding the specified variable were available. b (Ͼ50 × 10 9 /l for acute leukemia; Ͼ100 × 10 9 /l for chronic leukemia). tive studies from one single center are reported. 27, 30, 31 Two studied patients with leukemia. The first, involving 99 recipients of HLA-identical sibling transplants between 1981 and 1984, compared conventional to LAF isolation; 30 both groups received prophylactic systemic antibiotics. The second study, done between 1984 and 1987, included 342 recipients of HLA-identical sibling and alternative donor transplants and compared four strategies: conventional isolation, conventional isolation and prophylactic systemic antibiotics, LAF isolation, and LAF isolation and prophylactic systemic antibiotics. 31 Both studies evaluated events up to the time of engraftment and showed lower probabilities of bacteremia and other clinically significant infections with more intensive isolation; there was no survival benefit. A third study analyzed 100 patients with aplastic anemia treated with conventional isolation, conventional isolation and granulocyte transfusions or LAF isolation. 27 Compared to patients in conventional isolation, patients in LAF isolation had less bacteremia and other documented infections, less and delayed acute GVHD and higher probabilities of 100-day survival. Differences in GVHD and survival were of borderline statistical significance. Overall, results from the above studies are similar in direction and magnitude as those in the current IBMTR analysis. Although survival advantages in the prospective studies cited were not statistically significant, the large numbers of patients analyzed and longer follow-up in this study substantially increased our power to detect such differences. Our study did not elucidate the reasons for improved survival of patients in the HEPA/LAF cohort. In patients receiving transplants from donors other than an HLA-identical sibling, who are at high risk of invasive infections, 32, 33 we found fewer fungal pneumonias in the HEPA/LAF cohort. We lacked sufficient data to examine relative rates of bacterermia and other bacterial infections. Distribution of causes of death did not differ by isolation technique for either HLA-identical sibling or alternative donor transplants. We did not detect any difference in incidence or severity of GVHD. Experimental data show that GVHD may be reduced by a strictly sterile environment 34 but this is rarely attained in the clinical setting.
Our study found an inverse association between distance from the equator, ie geographic latitude, and TRM and 1-year mortality independent of the effect of isolation. Patients treated in warm climates may be at higher risk of exposure to airborne fungal spores. 35 However, the effect of HEPA/LAF was similar at warm and temperate latitudes.
The data analyzed have several limitations. First, we were unable to compare HEPA with LAF. This would be desirable since costs of these two techniques differ. We also did not have data on duration of isolation and insufficient data to assess influence of gut sterilization. However, neither oral nonabsorbable nor systemic antibiotics other than cotrimoxazole, both of which decrease gastrointestinal flora, seemed to impact TRM or survival. Finally, this was a non-randomized study. Although we carefully considered potential confounding by a large number of patient and treatment variables, it is possible that the observed effects are due to other unmeasured factors. The effects noted, however, are sufficiently strong to merit further study.
In conclusion, HEPA and/or LAF isolation appears to decrease TRM and increase survival after allogeneic bone marrow transplant. This benefit is stronger in patients receiving transplants from donors other than HLA-identical siblings. Further study is needed to determine whether HEPA and LAF differ, and to better define impact of prophylactic antibiotic regimens. As centres come under increasing pressure to control costs by eliminating costly supportive care measures, it is important to study carefully the impact of such changes on patient outcome.
